Cargando…

MYC translocation and/or BCL 2 protein expression are associated with poor prognosis in diffuse large B‐cell lymphoma

Genomic alterations and protein expression levels have been established as prognostic factors for survival in patients with diffuse large B‐cell lymphoma (DLBCL). In particular, double‐hit DLBCL (DHL), which exhibits translocations in MYC and BCL2 and/or BCL6, is known to be associated with a poor p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kawamoto, Keisuke, Miyoshi, Hiroaki, Yoshida, Noriaki, Nakamura, Naoya, Ohshima, Koichi, Sone, Hirohito, Takizawa, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968597/ https://www.ncbi.nlm.nih.gov/pubmed/27027803 http://dx.doi.org/10.1111/cas.12942

Ejemplares similares

DA-EPOCH-R therapy for high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in a patient with renal dysfunction
por: Mitobe, Masaki, et al.
Publicado: (2021)

Gemcitabine, Dexamethasone, and Cisplatin Regimen as an Effective Salvage Therapy for High-grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
por: Mitobe, Masaki, et al.
Publicado: (2018)

Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification
por: Miyaoka, Masashi, et al.
Publicado: (2022)

Combination of CD47 and signal‐regulatory protein‐α constituting the “don’t eat me signal” is a prognostic factor in diffuse large B‐cell lymphoma
por: Kazama, Ryo, et al.
Publicado: (2020)

Anaplastic large cell lymphoma, with 1,25(OH)((2))D((3))-mediated hypercalcemia: A case report
por: Mitobe, Masaki, et al.
Publicado: (2019)

Primary cutaneous diffuse large B‐cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression
por: Okada, Yosuke, et al.
Publicado: (2021)

Analysis of GNA13 Protein in Follicular Lymphoma and its Association With Poor Prognosis
por: Shimono, Joji, et al.
Publicado: (2018)

C-MYC, BCL2 and BCL6 Translocation in B-cell Non-Hodgkin Lymphoma Cases
por: Salam, Dayang Sharyati Datu Abdul, et al.
Publicado: (2020)

Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma
por: Zhang, YunXiang, et al.
Publicado: (2019)

Primary Chest Wall MYC/BCL6 Double-hit Lymphoma with t(3;7)(q27;p12) and t(8;14)(q24;q32) Translocations
por: Kamachi, Kazuharu, et al.
Publicado: (2019)

Clinical Applications of Genomic Alterations in ATLL: Predictive Markers and Therapeutic Targets
por: Yoshida, Noriaki, et al.
Publicado: (2021)

DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations
por: Akpa, Chidimma Agatha, et al.
Publicado: (2019)

C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma
por: Mohammed, Amrallah A, et al.
Publicado: (2019)

Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin
por: Wawire, Jonathan, et al.
Publicado: (2019)

Cladribine treatment for Erdheim–Chester disease involving the central nervous system and concomitant polycythemia vera: A case report
por: Tamura, Suguru, et al.
Publicado: (2018)

Artificial intelligence to detect MYC translocation in slides of diffuse large B-cell lymphoma
por: Swiderska-Chadaj, Zaneta, et al.
Publicado: (2020)

Spontaneous regression of diffuse large B-cell lymphoma in the small intestine with multiple lymphadenopathy
por: Tanaka, Yasuhiro, et al.
Publicado: (2019)

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab
por: Saburi, Masuho, et al.
Publicado: (2023)

High incidence of MYC and BCL2 abnormalities in mantle cell lymphoma, although only MYC abnormality predicts poor survival
por: Yi, Shuhua, et al.
Publicado: (2015)

The prognosis of MYC translocation positive diffuse large B‐cell lymphoma depends on the second hit
por: Clipson, Alexandra, et al.
Publicado: (2015)

Tumor microenvironment of adult T-cell leukemia/lymphoma
por: Takeuchi, Mai, et al.
Publicado: (2021)

MYC overexpression but not MYC/BCL2 double expression predicts survival in bulky mass diffuse large B‐cell lymphoma patients
por: Wang, Yanjie, et al.
Publicado: (2023)

Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors
por: Li, Weiping, et al.
Publicado: (2019)

Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019)

Burkitt lymphoma beyond MYC translocation: N-MYC and DNA methyltransferases dysregulation
por: De Falco, Giulia, et al.
Publicado: (2015)

New MYC IHC Classifier Integrating Quantitative Architecture Parameters to Predict MYC Gene Translocation in Diffuse Large B-Cell Lymphoma
por: Bigras, Gilbert, et al.
Publicado: (2018)

Clinicopathological analysis of polyploid diffuse large B-cell lymphoma
por: Shimono, Joji, et al.
Publicado: (2018)

Expression of telomerase reverse transcriptase in peripheral T‐cell lymphoma
por: Arakawa, Fumiko, et al.
Publicado: (2021)

Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification
por: Muto, Reiji, et al.
Publicado: (2018)

Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type
por: Wang, Jing-hua, et al.
Publicado: (2017)

Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement
por: Barouqa, Mohammad, et al.
Publicado: (2022)

Comprehensive genomic analysis identifying heterogeneity in peripheral T‐cell lymphoma
por: Yoshida, Noriaki, et al.
Publicado: (2021)

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?
por: Liu, Yanquan, et al.
Publicado: (2020)

“Double hit” B-lymphoblastic lymphoma with concurrent IGH/BCL2 and 8q24/MYC translocations: a case report
por: He, Lu, et al.
Publicado: (2021)

MYC Expression in Concert with BCL2 and BCL6 Expression Predicts Outcome in Chinese Patients with Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
por: Yan, Li-Xu, et al.
Publicado: (2014)

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
Publicado: (2016)

High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression
por: Maura, F, et al.
Publicado: (2017)

STX11 functions as a novel tumor suppressor gene in peripheral T-cell lymphomas
por: Yoshida, Noriaki, et al.
Publicado: (2015)

Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma
por: Ye, Qing, et al.
Publicado: (2015)

Combination of BCL-2 and MYC protein expression improves high-risk stratification in diffuse large B-cell lymphoma
por: Wang, Jing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_dsa2hnukss0rtivlkjskt38i8u